1782 related articles for article (PubMed ID: 8425972)
1. Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma.
Wolkenstein P; Chosidow O; Wechsler J; Guillaume JC; Lescs MC; Brandely M; Avril MF; Revuz J
J Am Acad Dermatol; 1993 Jan; 28(1):66-70. PubMed ID: 8425972
[TBL] [Abstract][Full Text] [Related]
2. [Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates].
Assmann K; Nashan D; Grabbe S; Luger TA; Metze D
Hautarzt; 2002 Aug; 53(8):554-7. PubMed ID: 12221472
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Phan GQ; Attia P; Steinberg SM; White DE; Rosenberg SA
J Clin Oncol; 2001 Aug; 19(15):3477-82. PubMed ID: 11481353
[TBL] [Abstract][Full Text] [Related]
4. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2.
O'Reilly F; Feldman E; Yang J; Hwu P; Turner ML
J Am Acad Dermatol; 2003 Apr; 48(4):602-4. PubMed ID: 12664026
[No Abstract] [Full Text] [Related]
5. Interleukin-2-associated bullous drug dermatosis.
Hofmann M; Audring H; Sterry W; Trefzer U
Dermatology; 2005; 210(1):74-5. PubMed ID: 15604553
[No Abstract] [Full Text] [Related]
6. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
[TBL] [Abstract][Full Text] [Related]
7. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
8. Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption.
Horn TD; Burke PJ; Karp JE; Hood AF
Arch Dermatol; 1991 Jan; 127(1):49-52. PubMed ID: 1824746
[TBL] [Abstract][Full Text] [Related]
9. [High-dose Roncoleukin in patients with disseminated cutaneous melanoma: a phase 1 study].
Moiseenko VM; Novik AV; Orlova RV; Protsenko SA; Mikhaĭlichenko TD; Semenova AI; Tiukavina NV
Vopr Onkol; 2005; 51(5):546-9. PubMed ID: 16756008
[TBL] [Abstract][Full Text] [Related]
10. IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters.
Dorval T; Mathiot C; Chosidow O; Revuz J; Avril MF; Guillaume JC; Tursz T; Brandely M; Pouillart P; Fridman WH
Biotechnol Ther; 1992; 3(1-2):63-79. PubMed ID: 1305893
[TBL] [Abstract][Full Text] [Related]
11. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
12. [Phase I trial of a recombinant human interleukin 2. Results in patients with disseminated solid tumors].
Tursz T; Dorval T; Berthaud P; Jouve M; Avril MF; Garcia-Giralt E; Le Chevalier T; Spielmann M; Sevin D; Palangie T
Presse Med; 1991 Feb; 20(6):250-4. PubMed ID: 1826163
[TBL] [Abstract][Full Text] [Related]
13. [Interleukin-2 immunotherapy and cutaneous manifestations].
Larbre B; Nicolas JF; Sarret Y; Tognet E; Mercatello A; Thivolet J
Ann Dermatol Venereol; 1993; 120(8):528-33. PubMed ID: 8304709
[TBL] [Abstract][Full Text] [Related]
14. The skin: an immunoreactive target organ during interleukin-2 administration?
Dummer R; Miller K; Eilles C; Burg G
Dermatologica; 1991; 183(2):95-9. PubMed ID: 1743379
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
16. Seborrheic dermatitis-like eruption following interleukin-2 administration.
Kawakami Y; Nakamura-Wakatsuki T; Yamamoto T
Dermatol Online J; 2010 Sep; 16(9):12. PubMed ID: 20875333
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Hess V; Herrmann R; Veelken H; Schwabe M
Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
[TBL] [Abstract][Full Text] [Related]
18. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
Garrido MC; Gutierrez C; Riveiro-Falkenbach E; Ortiz P; Rodriguez-Peralto JL
Am J Dermatopathol; 2015 Oct; 37(10):795-8. PubMed ID: 26381028
[TBL] [Abstract][Full Text] [Related]
19. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
[TBL] [Abstract][Full Text] [Related]
20. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
